Lupin said the US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
“This is a significant milestone as we build back our reputation of being best-in-class in Quality and Compliance. We are committed to manufacture and supply products of the highest quality from all our manufacturing sites.” said Vinita Gupta, CEO, Lupin.
Commenting on the development, Nilesh Gupta, managing director, Lupin said: “This is a very positive development and we are delighted with the news of the change in classification of our Goa site. The Goa site has a very important place in the US market with the number of affordable, quality medicines we supply, and we now look forward to new products flowing out of the site again.”
Shares of Lupin had hit a 52-week low of Rs 854 on December 7, 2021. It touched a 52-week high of Rs 1,267.50 on June 2, 2021. Despite of today’s gain, the stock has underperformed the market by falling 18 per cent in past six months, as compared to 10.5 per cent rally in the S&P BSE Sensex. In the last one year, however, it has gained 3 per cent, against 26 per cent surged in the benchmark index.
"Lupin plans to strengthen the biosimilars portfolio across, especially in EU and the US apart from continued respiratory traction in the US. Its tie-ups with Eli Lilly, Boehringer for anti-diabetics and with MSD for pneumonia vaccines will help bolster domestic franchise and the progress on the margins front are key triggers for future price performance," ICICI Securities said in Q2FY22 result update.
At 10:20 am; the stock traded 7 per cent higher at Rs 944, as compared to 0.63 per cent decline in the S&P BSE Sensex. The trading volumes on the counter jumped over five-fold with a combined 4.96 million equity shares changed hands on the NSE and BSE.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in